NEW RAY MED-NEW (06108) announced its interim results for 2025, reporting revenue of HK$44.701 million, representing a year-on-year increase of 167.4%. The company recorded a net loss of HK$7.454 million, which widened by 82.3% compared to the same period last year. Basic loss per share was HK$0.45 cents.

The increase in revenue during the period was attributed to the group's launch of new products in China starting from the second half of 2024. However, this growth was partially offset by declining demand for these products during the period, which was caused by the continued adverse impact from the further strengthening of antimicrobial stewardship policies across multiple regions in mainland China.